302 related articles for article (PubMed ID: 37698749)
21. Isolation, Purification, Characterisation and Application of L-ASNase: A Review.
Paul T; Mondal A; Bandyopadhyay TK
Recent Pat Biotechnol; 2019; 13(1):33-44. PubMed ID: 30318009
[TBL] [Abstract][Full Text] [Related]
22. Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
Mondelaers V; Ferster A; Uyttebroeck A; Brichard B; van der Werff Ten Bosch J; Norga K; Francotte N; Piette C; Vandemeulebroecke K; Verbeke C; Schmidt S; Benoit Y; Lammens T; De Moerloose B
Br J Haematol; 2020 Jul; 190(1):105-114. PubMed ID: 32057100
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.
Schrey D; Borghorst S; Lanvers-Kaminsky C; Hempel G; Gerss J; Möricke A; Schrappe M; Boos J
Pediatr Blood Cancer; 2010 Jul; 54(7):952-8. PubMed ID: 20108339
[TBL] [Abstract][Full Text] [Related]
24. Development of Escherichia coli asparaginase II for the Treatment of Acute Lymphocytic Leukemia: In Silico Reduction of asparaginase II Side Effects by a Novel Mutant (V27F).
Ardalan N; Akhavan Sepahi A; Khavari-Nejad RA
Asian Pac J Cancer Prev; 2021 Apr; 22(4):1137-1147. PubMed ID: 33906306
[TBL] [Abstract][Full Text] [Related]
25. Asparaginase activities during intensified treatment with pegylated
Lanvers-Kaminsky C; Niemann A; Eveslage M; Beck J; Köhnke T; Martin S; de Wit M; Spriewald B; Hauspurg H; Hoelzer D; Boos J; Gökbuget N
Leuk Lymphoma; 2020 Jan; 61(1):138-145. PubMed ID: 31480965
[TBL] [Abstract][Full Text] [Related]
26. Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer.
Costa-Silva TA; Costa IM; Biasoto HP; Lima GM; Silva C; Pessoa A; Monteiro G
Blood Rev; 2020 Sep; 43():100651. PubMed ID: 32014342
[TBL] [Abstract][Full Text] [Related]
27. L-asparaginase from
Saeed H; Elsawy E; Shalaby M; Abdel-Fattah M; Hemida A; Eldoksh A; Ataya FS; Nematalla H; Elkewedi M; Labrou NN; El-Nikhely N
Prep Biochem Biotechnol; 2022; 52(6):668-680. PubMed ID: 34612174
[TBL] [Abstract][Full Text] [Related]
28. Engineering and Expression Strategies for Optimization of L-Asparaginase Development and Production.
Shishparenok AN; Gladilina YA; Zhdanov DD
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894901
[TBL] [Abstract][Full Text] [Related]
29. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia.
Raetz EA; Salzer WL
J Pediatr Hematol Oncol; 2010 Oct; 32(7):554-63. PubMed ID: 20724951
[TBL] [Abstract][Full Text] [Related]
30. Population pharmacokinetics of native Escherichia coli asparaginase.
Borghorst S; Pieters R; Kuehnel HJ; Boos J; Hempel G
Pediatr Hematol Oncol; 2012 Mar; 29(2):154-65. PubMed ID: 22376019
[TBL] [Abstract][Full Text] [Related]
31. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia.
Dibenedetto SP; Di Cataldo A; Ragusa R; Meli C; Lo Nigro L
J Clin Oncol; 1995 Feb; 13(2):339-44. PubMed ID: 7844595
[TBL] [Abstract][Full Text] [Related]
32. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.
Avramis VI; Tiwari PN
Int J Nanomedicine; 2006; 1(3):241-54. PubMed ID: 17717965
[TBL] [Abstract][Full Text] [Related]
33. Extended Stability of Reconstituted Lyophilized Erwinia L-asparaginase in Vials.
ViÑa-Romero MM; Ramos-Diaz R; Mourani-Padron I; Gonzalez-Mendez H; Gonzalez-Cruz M; Nazco-Casariego GJ; Merino-Alonso JF; Diaz-Vera J; GutiÉrrez-NicolÁs F
In Vivo; 2020; 34(5):2419-2421. PubMed ID: 32871767
[TBL] [Abstract][Full Text] [Related]
34. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
Ko RH; Jones TL; Radvinsky D; Robison N; Gaynon PS; Panosyan EH; Avramis IA; Avramis VI; Rubin J; Ettinger LJ; Seibel NL; Dhall G
Cancer; 2015 Dec; 121(23):4205-11. PubMed ID: 26308766
[TBL] [Abstract][Full Text] [Related]
35. Back to the future: the amazing journey of the therapeutic anti-leukemia enzyme asparaginase
Tong WH; Rizzari C
Haematologica; 2023 Oct; 108(10):2606-2615. PubMed ID: 37470157
[TBL] [Abstract][Full Text] [Related]
36. Heterologous expression of fungal L-asparaginase: a systematic review.
Rodrigues Andrade KC; Cordeiro de Abreu JA; Guimarães MB; Abrunhosa LS; Leôncio Rodrigues AL; Fonseca-Bazzo YM; Silveira D; Souza PM; Magalhães PO
Future Microbiol; 2024 Jan; 19():157-171. PubMed ID: 37882841
[TBL] [Abstract][Full Text] [Related]
37. Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia.
Bushman JE; Palmieri D; Whinna HC; Church FC
Leuk Res; 2000 Jul; 24(7):559-65. PubMed ID: 10867129
[TBL] [Abstract][Full Text] [Related]
38. Microbial L-asparaginase as a promising enzyme for treatment of various cancers.
Darvishi F; Jahanafrooz Z; Mokhtarzadeh A
Appl Microbiol Biotechnol; 2022 Sep; 106(17):5335-5347. PubMed ID: 35871694
[TBL] [Abstract][Full Text] [Related]
39. Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum.
Lanvers C; Vieira Pinheiro JP; Hempel G; Wuerthwein G; Boos J
Anal Biochem; 2002 Oct; 309(1):117-26. PubMed ID: 12381370
[TBL] [Abstract][Full Text] [Related]
40. L-asparaginase: an effective agent in the treatment of acute lymphoblastic leukemia.
Kumar K; Kaur J; Walia S; Pathak T; Aggarwal D
Leuk Lymphoma; 2014 Feb; 55(2):256-62. PubMed ID: 23662993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
